Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00675428 · FLOW

Participant flow

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma · Source last updated 2014-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
    id
    FG000
    title
    Natalizumab 300 mg
  2. description
    Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
    id
    FG001
    title
    Natalizumab 450 mg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        2
      type
      Disease Progression
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      No Disease Response After Cycle 6
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      type
      Physician Decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
This record includes data up to and including the last data values collected during long-term follow-up (27 January 2010).
Complete source fields
groups
  1. description
    Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
    id
    FG000
    title
    Natalizumab 300 mg
  2. description
    Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
    id
    FG001
    title
    Natalizumab 450 mg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        2
      type
      Disease Progression
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      No Disease Response After Cycle 6
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      type
      Physician Decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
This record includes data up to and including the last data values collected during long-term follow-up (27 January 2010).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice